RightFit
RecruitingPhase not listed

PPD™ CorEvitas™ Psoriasis (PSO) Rapid Response Non-Interventional Study

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This 16-week study follows adults starting a new advanced treatment for moderate to severe plaque psoriasis, a skin condition that causes thick, scaly patches. It collects information from patients and their skin doctors before and during treatment.

This is a 16-week prospective, single-arm cohort, study of patients initiating advanced therapy for the treatment of moderate-to-severe plaque PSO. Eligible patients must be willing to be seen in-person by their treating physician for a Baseline visit (with first dose of the advanced therapy occurring within 14 days), and at 2 (+/- 5 days), 4 (+/- 5 days), and 16 weeks (+14 days) calculated based on date of first dose of the advanced therapy and must provide informed consent prior to enrolling in the study or completing study-specific questionnaires or procedures. Data will be collected from both subjects and their treating dermatology provider at predetermined scheduled intervals (Baseline, Week 2, Week 4, and Week 16) using a structured and standardized data collection tool.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • You are at least 18 years old.
  • You have moderate to severe plaque psoriasis, with a doctor's skin rating of 3 or 4.
  • You are starting a medicine allowed in this study that you have not used before.
  • You are willing and able to give informed consent, meaning you understand the study and agree to join.
  • You can visit your skin doctor in person at the start and about 2, 4, and 16 weeks after your first dose.

Who can't join

  • You are in a blinded clinical trial, where you or the study team does not know which treatment you receive.
  • You do not get at least one dose of the advanced treatment within 14 days after your first study visit.
  • You are currently enrolled in the CorEvitas PSO Registry. You cannot be in both programs at the same time.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: The inclusion criteria for this study will be as follows: 1. Patient is at least 18 years of age at the time of study enrollment 2. Patient has a diagnosis of moderate to severe plaque psoriasis based on an Investigator Global Assessment (IGA, part of routine care) score of 3 or 4 at the time of Enrollment. 3. Patient is initiating new Eligible Medication for the first time for the treatment of PSO. 4. Patient is willing and able to provide informed consent to participate in this study. 5. Patient is willing to be seen in-person by their treating dermatology provider at two (2), four (4), and sixteen (16) weeks following initiation of the advanced therapy. Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in the study: 1. Patient is participating in a blinded clinical trial. 2. Patients that do not receive at least 1 dose of the advanced therapy within 14 days following the Enrollment/Baseline visit for the study. 3. Patients cannot be concurrently enrolled in both the CorEvitas PSO Registry and the CorEvitas Psoriasis (PSO) Rapid Response Non-Interventional Study. A. Patients currently enrolled in the CorEvitas PSO Registry are ineligible for participation in the CorEvitas Psoriasis (PSO) Rapid Response Non-Interventional Study. B. Patients otherwise meeting eligibility criteria can be enrolled in the CorEvitas Psoriasis (PSO) Rapid Response Non-Interventional Study C. Following completion or at time of Exit from the CorEvitas Psoriasis (PSO) Rapid Response Non Interventional Study, patients will be eligible to enroll into the CorEvitas PSO Registry for long term follow up at the standard of care cadence supported by the registry. A separate Informed consent will be obtained.

Study sites (1)

MA